US Drug Watchdog Wants to Hear from Users of the Drug Prolia if Their Healthcare Provider is Now Charging Them More than $3000 Per Does and or Requiring a Needless Infusion Center-HHS Secretary Kennedy-Pay Attention

June 11, 2025 07:45 PM AEST | By EIN Presswire
 US Drug Watchdog Wants to Hear from Users of the Drug Prolia if Their Healthcare Provider is Now Charging Them More than $3000 Per Does and or Requiring a Needless Infusion Center-HHS Secretary Kennedy-Pay Attention
Image source: EIN Presswire

WASHINGTON , DC, UNITED STATES, June 11, 2025 /EINPresswire.com/ -- The US Drug Watchdog says, "If you are a user of the osteoporosis drug Prolia and you are now paying more than $3000 per dose please contact us-especially if you are now required to go to an infusion center rather than receiving this medication at your doctor’s office. We have been assisting recipients of this medicine for a few years, and we do not understand the enormous price fluctuations involving this drug. Nor do we understand why some healthcare providers are requiring this medication to be administered by an infusion center, rather than a doctor’s office.

"Based on our research the cost for a single dose of Prolia is around $2000. How is it possible some healthcare companies are charging patients as much or more than $5000 per dose and-how is it possible Medicare-Medicaid and or private insurance companies are paying what appears to be a greatly inflated price? Much to our surprise every time we get involved in one of these bills-the healthcare provider drops the charges.

"We do not believe the makers of Prolia are directly involved but we are convinced middlemen healthcare providers are--and these insane markups need to stop. We are requesting Health & Human Services Secretary Kennedy, and the Trump Administration get involved. We believe the up charging of the drug Prolia is the tip of the iceberg, and we are convinced middlemen healthcare providers are doing the same on hundreds of other drugs and or medications nationwide in the USA.

"Based on our research the drug Prolia might cost about $950 in Canada. In the USA the drug costs about $2000. How is this possible?" https://USDrugWatchdog.Com

The US Drug Watchdog believes the Trump Administration's DOGE initiative has only scratched the surface when it comes to the US Taxpayer being gouged, especially when it comes to spending hard earned tax dollars on healthcare costs related to Medicare and Medicaid recipients. We believe the Trump Administration and Secretary Kennedy are very serious about lowering the cost of healthcare in the United States. One great way would be to negotiate the price of prescription drugs for Medicare and Medicaid recipients---so that at the end of the day the US Taxpayer is not getting ripped off. http://USDrugWatchdog.Com

Michael Thomas
US Drug Watchdog
+1 866-714-6466
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.